Handel Syndax Pharmaceuticals, Inc. - SNDX CFD

Warunki handlu

• Typ: CFD
• Spread: 0.13
• Korekta finansowania pozycji długiej overnight: -0.02154%
• Korekta finansowania pozycji krótkiej overnight: -0.00068%
• Korekta finansowania overnight: 21:00 (UTC)
• Waluta: USD
• Min. wielkość handlu: 1
• Depozyt zabezpieczający: 50.00%
• Giełda papierów wartościowych: United States of America
• Prowizja od transakcji: 0%
• Opłata za gwarantowany stop: 1%

Najważniejsze statystyki

• Poprz. zamknięcie: 21.06
• Otwarcie: 20.7
• Zmiana 1 r.: 54.59%
• Zakres dzienny: 20.35 - 20.86

Handel Syndax Pharmaceuticals, Inc. - SNDX CFD

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.